NCT06621017View on ClinicalTrials.gov

Effect of GLP-1 Analogue ROSE-010 on Appetite in Overweight and Obese Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 26, 2024

Primary Completion Date

February 27, 2025

Study Completion Date

February 27, 2025

Conditions
Obesity; Overweight
Interventions
DRUG

ROSE-010 99 mcg

Sub-cutaneous injection of ROSE-010 solution

DRUG

Placebo

Sub-cutaneous injection of saline solution

DRUG

ROSE-010 150 mcg

Sub-cutaneous injection of ROSE-010 solution

Trial Locations (1)

45227

Medpace Clinical Pharmacology, Cincinnati

All Listed Sponsors
lead

Rose Pharma Inc

INDUSTRY

NCT06621017 - Effect of GLP-1 Analogue ROSE-010 on Appetite in Overweight and Obese Subjects | Biotech Hunter | Biotech Hunter